SLC25A20 and urinary bladder carcinoma: The tissue mRNA expression related to acylcarnitine and carnitine metabolism (CPT1, CPT2, carnitine/acylcarnitine translocase) were downregulated, which the author proposed to result in elevated urinary acylcarnitine excretion from bladder cancer tissue.39